- Published: Wednesday, 03 October 2018 11:55
- Hits: 104
- Published: Wednesday, 26 September 2018 09:12
- Hits: 159
at the Martinos Center at MGH, Boston during the next three years.
The aim of this proposal is to investigate basic pharmacological mechanisms and brain network effects of drugs used in classical and novel treatment of major depressive disorder (MDD). Furthermore, I will identify the effects of different 5-HT2AR agonists on functional brain connectivity which will reveal how intracellular pathways govern brain connectivity.
The classical pharmacological treatment strategy for MDD patients is the administration of SSRIs whereas hallucinogens (5-HT2AR agonists) are currently being investigated for their SSRIs whereas hallucinogens (5-HT2AR agonists) are currently being investigated for their treatment potential in various psychiatric disorders. For both SSRIs and hallucinogens, the mechanism of action is incompletely understood and for the hallucinogens this is further complicated by the fact that these 5-HT2AR agonists can differentially activate intracellular pathways - a phenomenon known as functional selectivity.
I will use hybrid positron emission tomography (PET) and magnetic resonance (MR) neuroimaging to study drug effects in vivo in humans and in non-human primates. In healthy volunteers, I will study the dose-dependent effects of citalopram administration: Changes in neuronal activation and brain circuitries will be measured with MRI and these changes will be related to the serotonin transporter occupancy measured by the PET radioligand [11C]DASB. In non-human primates, we will measure the 5-HT2AR occupancy, the hemodynamic response and changes in brain networks upon administration of two 5-HT2AR agonists: The hallucinogenic 25CN-NBOH and the non-hallucinogenic lisuride.
Identification of brain responses to these two types of anti-depressive drugs will give valuable insight into the spatial and temporal mode of action of these drugs. The outcome of this study will generate critical new information about how the involved brain circuits are affected by the pharmacological intervention and will lay the basis for a personalized medicine approach to patients with MDD.
- Published: Monday, 27 August 2018 12:04
- Hits: 286
Liv did a great job at the defense and afterwards NRU celebrated her with a reception.
Liv replying wisely to Kelly Rohan's questions.
- Published: Thursday, 16 August 2018 14:34
- Hits: 351
Professor Lammertsma is world-wide recognized as one of the leading figures within development of PET methodology and its applications for translational experimental medicine across a range of clinical disciplines, but particularly
for brain disorders. He has imposed internationally a culture of rigor for the quantification of regional tissue function using PET.
- Published: Friday, 27 July 2018 12:11
- Hits: 342
- Published: Monday, 02 July 2018 15:30
- Hits: 422
- Published: Tuesday, 12 June 2018 08:56
- Hits: 453
- Published: Friday, 01 June 2018 11:22
- Hits: 416
We are very glad to welcome our summer interns:
Niki Stypidou, bachelor student in Neuroscience at the University of Edinburgh. She will join NRU in June and July, primarily assisting the Sleep project.
Sara Bakalchuk, a rising senior and neuroscience major from Wesleyan University in USA where she has shadowed in a research lab studying obesity and addiction in rats. Her main scientific interests include neuroanatomy, neuroimaging and clinical neuroscience. Sara will be at NRU until mid August.
- Published: Friday, 04 May 2018 15:34
- Hits: 498
Synapses are the points of communication between brain cells and they are subject to adaptations, known as synaptic plasticity. Recently, it has become possible to assess presynaptic density in the living human brain with the synaptic vesicle glycoprotein 2A (SV2A) radioligand, 11C-UCB-J and positron emission tomography (PET). We here propose a project with three aims:
1) to determine if cerebral SV2A density is preserved in healthy ageing across.
2) to investigate if short-term sensory deprivation is associated with a compensatory increase in cerebral SV2A density, and if the ability to induce synaptic plasticity is related to APOE/BDNF genotypes.
3) to uncover if cerebral SV2A density is decreased in hippocampus/entorhinal cortex in elderly people at risk for Alzheimer’s Disease.
Knowledge about development of synaptic plasticity in human brain will critically inform us about not only about neurorehabilitation potential, but also about how and when neurodegeneration emerges.
- Published: Monday, 23 April 2018 11:31
- Hits: 513
Olaf got his honorary diploma handed over by Jesper Erdal, who is the president of the DNS.
More Articles ...
- Large grant to Melanie Ganz from the Elsass Foundation
- Two grants to support joint research with Profs Robbins and Sahakian
- Funding from RH
- Funding from Augustinus Fonden
- PhD defence: Vincent Beliveau
- PhD defence: Louise Møller Jørgensen
- Historical EU-funding for NRU post docs
- Two FSS grants to NRU researchers
- Travel grant to NRU from the Lundbeck Foundation
- NRU X-mas symposium Dec 8